A Nov. 3 headline put Genmab and two other oncology biotech companies in focus. But the supplied information doesn’t name the other companies or explain what prompted the headline.
The headline describes a “stock-price shock,” but the facts provided don’t identify a specific event behind it. Genmab’s latest listed close was US$54.38, and the supplied figures show gains over several periods.
Investor takeaway: The headline draws attention to Genmab and two unnamed peers, but the information provided doesn’t establish a new company-specific catalyst or explain the stock move.
Genmab AS
GMAB.US
GMAB.US
Genmab AS
WealthAwesomeMarket cap
$34.14B
P/E
43.4x
52W high
$59.97
52W low
$23.62
1W change
+24.29%
Beta
0.55
Analyst Price Targets
Based on 12 analysts covering GMAB · as of Nov 3, 2026
Wall Street analysts forecast GMAB stock price to rise 17.0% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
C$64.96
+17.0% Upside
Previously C$64.65 on Nov 2, 2026
Current Price
C$55.52
Last close
Analyst Breakdown (12 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GMAB's historical volatility
30-Day Vol
85.2%
Annualized
90-Day Vol
55.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$66.37
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$58.93 | C$43.92 – C$79.05 |
| 60 trading days | C$62.54 | C$41.27 – C$94.76 |
| 90 trading days | C$66.37 | C$39.90 – C$110.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
US$54.38 latest close; 0.49x the 20-day average volume
Genmab’s latest listed close was US$54.38. Volume was 731,126 shares, compared with a 20-day average of 6,182,661 shares. The supplied volume comparison is 0.49x.
Bull case
Genmab shares are up 59.77% over one month and 74.48% year to date. The latest listed close was US$54.38.
Bear case
The headline doesn’t name a specific catalyst. Latest volume was 731,126 shares, below the 20-day average of 6,182,661.
What the Nov. 3 headline says—and leaves unclear
The EOD headline published on Nov. 3, 2026, reads: “Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus.” It puts Genmab among three oncology biotech companies, but the supplied information doesn’t name the other two, explain the alleged price shock, or describe a new Genmab announcement. The headline alone doesn’t establish what happened or what caused the attention.
Earlier headlines in the supplied list mention trial results and a 52-week high. Those are background items and don’t explain the Nov. 3 headline. Investors can follow the company’s listed figures on the Genmab stock page.
The supplied price and volume figures
Genmab’s latest listed close was US$54.38. The supplied performance data show a 1.09% gain in one day, 24.29% over one week, 59.77% over one month, and 74.48% year to date.
Latest volume was 731,126 shares, compared with a 20-day average of 6,182,661. The supplied comparison is 0.49x. The close was within a 52-week range of US$23.62 to US$59.97, at 85% of that range. These figures describe recent trading but don’t explain what prompted the headline.
What to watch for next
The key unanswered questions are which two other oncology biotech companies the headline refers to and what it means by a stock-price shock. The supplied information includes no follow-up announcement, named catalyst, or details linking the headline to a specific Genmab development. Any further interpretation would require information beyond what’s provided here. The Genmab company page lists the supplied company and share data.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
